Search filters

List of works by Yasuhiro Oki

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

scientific article published on 09 May 2019

A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma

scientific article published on 5 April 2018

ABVD plus rituximab ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

scientific article published on 06 September 2018

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center

scientific article published on 25 August 2005

Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma

scientific article published on 5 March 2015

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

scientific article

Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma.

scientific article published on 6 April 2017

Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma

scientific article published on 13 March 2012

Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.

scientific article

Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma

scientific article published on 30 November 2015

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden

scientific article published on 14 August 2018

Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et al.

scientific article

De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era

scientific article published on 18 September 2019

Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach

scientific article published on 29 March 2015

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions.

scientific article published on 22 April 2017

Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma

scientific article

Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.

scientific article published on 9 August 2016

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

scientific article published on 20 May 2016

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

scientific article

Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review

scientific article

Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?

scientific article published on 18 August 2017

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma

scientific article published on 18 May 2017

Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma

scientific article published on 27 March 2015

Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma ⬇️

scientific article published on March 1, 2012

Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma

scientific article

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study

scientific article published on 24 March 2017

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

scientific article published on 27 November 2015

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial

scientific article

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis.

scientific article published on 22 June 2018

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

scientific article

Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial

scientific article published on 28 March 2019

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.

scientific article published on May 2015

Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.

scientific article

Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes

scientific article

Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.

scientific article published on 28 June 2016

Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.

scientific article

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

scientific article published on 25 October 2011

Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy

scientific article published on 04 April 2018

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

scientific article published on 08 July 2014

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial

scientific article

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

scientific article

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

scientific article

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

scientific article published on 3 May 2018

Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma

scientific article

Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma

scientific article

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma

scientific article published on 02 March 2018

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

scientific article

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

scientific article published on 27 July 2015

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

scientific article published on March 2007

Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.

scientific article published on 9 August 2017

Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL

scientific article published on 01 June 2018

Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy

scientific article published on 14 March 2018

Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma

scientific article published on May 2015

Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure<sup/>

scientific article published on 26 April 2018

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.

scientific article published on 22 July 2016

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

scientific article published on October 2013

Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma.

scientific article published on 6 January 2018

Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma.

scientific article published on 9 May 2017

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy

scientific article published on 12 July 2018

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

scientific article

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

scientific article published on 14 October 2020

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

scientific article

Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography

scientific article published on May 2015

Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement

scientific article published on 05 July 2018

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

scientific article published on 08 January 2019

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

scientific article published on 06 January 2014

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma

scientific article published on 14 March 2018

The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.

scientific article

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

scientific article published on 3 April 2017

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

scientific article published on 21 February 2018

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

scientific article published on 19 March 2019

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.

scientific article published on 10 June 2015

Paulina is supported by:

About Paulina

Help